Inotiv Inc (NOTV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inotiv Inc (NOTV) has a cash flow conversion efficiency ratio of -0.014x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.07 Million) by net assets ($77.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Inotiv Inc's balance sheet to measure how much of total assets are equity-financed.
Inotiv Inc - Cash Flow Conversion Efficiency Trend (1997–2025)
This chart illustrates how Inotiv Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check NOTV cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Inotiv Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inotiv Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Heritage Distilling Holding Company, Inc.
NASDAQ:IPST
|
-0.076x |
|
Barakah Offshore Petroleum Bhd
KLSE:7251
|
0.017x |
|
Investment Friends Capital SE
WAR:IFC
|
0.002x |
|
Virax Biolabs Group Limited Ordinary Shares
NASDAQ:VRAX
|
-0.576x |
|
BEACN Wizardry & Magic Inc
V:BECN
|
2.904x |
|
Internet Gold Golden Lines Ltd
TA:IGLD
|
1.079x |
|
American Rebel Holdings Inc
NASDAQ:AREB
|
-0.143x |
|
Avidian Gold Corp
V:AVG
|
-0.020x |
Annual Cash Flow Conversion Efficiency for Inotiv Inc (1997–2025)
The table below shows the annual cash flow conversion efficiency of Inotiv Inc from 1997 to 2025. For the full company profile with market capitalisation and key ratios, see Inotiv Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $136.03 Million | $-10.46 Million | -0.077x | -92.58% |
| 2024-09-30 | $170.50 Million | $-6.80 Million | -0.040x | -138.43% |
| 2023-09-30 | $268.49 Million | $27.88 Million | 0.104x | +816.16% |
| 2022-09-30 | $359.77 Million | $-5.22 Million | -0.015x | -114.19% |
| 2021-09-30 | $105.13 Million | $10.75 Million | 0.102x | -39.81% |
| 2020-09-30 | $7.60 Million | $1.29 Million | 0.170x | +2.35% |
| 2019-09-30 | $10.71 Million | $1.78 Million | 0.166x | -48.21% |
| 2018-09-30 | $10.88 Million | $3.49 Million | 0.320x | +119.47% |
| 2017-09-30 | $8.47 Million | $1.24 Million | 0.146x | +2.71% |
| 2016-09-30 | $7.46 Million | $1.06 Million | 0.142x | -25.00% |
| 2015-09-30 | $10.72 Million | $2.03 Million | 0.189x | +7.31% |
| 2014-09-30 | $9.54 Million | $1.68 Million | 0.177x | +9.97% |
| 2013-09-30 | $9.46 Million | $1.52 Million | 0.161x | +870.02% |
| 2012-09-30 | $9.59 Million | $-200.00K | -0.021x | -129.88% |
| 2011-09-30 | $15.59 Million | $1.09 Million | 0.070x | -69.50% |
| 2010-09-30 | $10.67 Million | $2.44 Million | 0.229x | +16.05% |
| 2009-09-30 | $13.12 Million | $2.59 Million | 0.197x | +486.76% |
| 2008-09-30 | $17.80 Million | $598.00K | 0.034x | -78.71% |
| 2007-09-30 | $18.55 Million | $2.93 Million | 0.158x | -28.76% |
| 2006-09-30 | $17.35 Million | $3.84 Million | 0.222x | +902.04% |
| 2005-09-30 | $19.60 Million | $-541.25K | -0.028x | -118.93% |
| 2004-09-30 | $19.42 Million | $2.83 Million | 0.146x | -2.26% |
| 2003-09-30 | $19.73 Million | $2.95 Million | 0.149x | +38.82% |
| 2002-09-30 | $18.90 Million | $2.03 Million | 0.108x | -52.39% |
| 2001-09-30 | $17.83 Million | $4.03 Million | 0.226x | +772.94% |
| 2000-09-30 | $16.06 Million | $-539.16K | -0.034x | -136.51% |
| 1999-09-30 | $17.40 Million | $1.60 Million | 0.092x | -35.63% |
| 1998-09-30 | $16.80 Million | $2.40 Million | 0.143x | +23.21% |
| 1997-09-30 | $6.90 Million | $800.00K | 0.116x | -- |
About Inotiv Inc
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences researc… Read more